BIOMAT Database Logo BIOMAT Database Logo

Specific adoptive immunotherapy. 1989

P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Department of Medicine, University of Washington, Seattle.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D005622 Friend murine leukemia virus A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice. Friend Virus,Rowson-Parr Virus,Rowson Parr Virus,Virus, Friend,Virus, Rowson-Parr

Related Publications

P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy with virus-specific T cells.
September 2011, Best practice & research. Clinical haematology,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive cellular immunotherapy with CD19-specific T cells.
January 2005, Klinische Padiatrie,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Specific adoptive immunotherapy: experimental basis and future potential.
January 1982, Survey of immunologic research,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
May 1999, The Pediatric infectious disease journal,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
January 1994, Cancer chemotherapy and biological response modifiers,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
January 1996, Cancer chemotherapy and biological response modifiers,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
January 1999, Cancer chemotherapy and biological response modifiers,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
May 1989, Lancet (London, England),
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
November 1997, Current opinion in oncology,
P D Greenberg, and J P Klarnet, and D E Kern, and K Okuno, and S Riddell, and M A Cheever
Adoptive immunotherapy.
May 1989, Lancet (London, England),
Copied contents to your clipboard!